Soubeyran I, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J M
Fondation Bergonié, Comprehensive Cancer Center, Bordeaux, France.
Breast Cancer Res Treat. 1995 May;34(2):119-28. doi: 10.1007/BF00665784.
To assess the practical prognostic value of pS2, we evaluated its expression by immunohistochemistry in paraffin-embedded tissue from 942 previously untreated invasive ductal carcinomas (IDC) resected in our center between 1980 and 1986. Positive staining of tumor cells was found in 684 cases (73%), but most of the tumors contained only a small amount of positive cells. There was a negative correlation between pS2 and tumor size (p = 0.01) and histological grade (p < 0.0001), and a positive correlation between pS2 and hormonal receptor status (p < 0.001). With respect to overall survival, pS2 positivity was associated with a better prognosis for the whole group and the node-positive sub-group. However, in terms of relapse and metastasis, pS2 was not significant. Furthermore, in multivariate analysis including tumor size, nodal status, histological grade, ER status, PR status, chemotherapy, hormonal treatment, and pS2, the latter appears to be of no prognostic value.
为评估pS2的实际预后价值,我们采用免疫组化法对1980年至1986年间在本中心切除的942例未经治疗的浸润性导管癌(IDC)石蜡包埋组织中的pS2表达进行了评估。684例(73%)肿瘤细胞呈阳性染色,但大多数肿瘤中仅含有少量阳性细胞。pS2与肿瘤大小(p = 0.01)和组织学分级(p < 0.0001)呈负相关,与激素受体状态呈正相关(p < 0.001)。就总生存期而言,pS2阳性与整个组和淋巴结阳性亚组的较好预后相关。然而,在复发和转移方面,pS2无显著意义。此外,在包括肿瘤大小、淋巴结状态、组织学分级、雌激素受体状态、孕激素受体状态、化疗、激素治疗和pS2的多因素分析中,pS2似乎没有预后价值。